Pediatric Use Alternatives Should Not Be Required In Labeling - PhRMA
This article was originally published in The Tan Sheet
Executive Summary
FDA's requirement for labeling to recommend preferential use of competitor products that have positive pediatric data would make it appear the subject drug has been found inferior in comparative trials, the Pharmaceutical Research & Manufacturers of America maintains in comments on FDA's pediatric rule draft guidance.
You may also be interested in...
Pediatric rule
FDA draft guidance on pediatric rule compliance slated for publication in Dec. 4 Federal Register. Published in December 1998, the rule requires that pediatric assessments be included in all NDAs, as well as ANDAs based on suitability petitions for a change in active ingredient, dosage form or route of administration, that are filed after Dec. 2. Although the guidance does not address ANDA suitability petitions, it provides an overview of pediatric assessments, describes waiver/deferral procedures and discusses interactions between the rule and FDAMA pediatric exclusivity requirements
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands